Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program

ORLEANS, Ontario, Feb. 12, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced accelerated development of its second-generation drug inhalation program for fibromyalgia and uncontrolled pain over the last months. 

A Phase 1 study in healthy volunteers using vaporized PPP001 was successfully completed (click here) and the Corporation filed a patent application after unexpectedly discovering the unique composition of cannabis smoke.  In July 2018, the Corporation entered into a co-development agreement with Storz Bickel, widely recognized as the global leader in vaporizer design and manufacturing. Tetra incorporated the vaporizer into its smoke-vapor research program as it aimed to understand how inhaled cannabis relieves pain for patients.

About Neuropathic Pain (Fibromyalgia) and Chronic Pain
Fibromyalgia affects about 4 million U.S. adults or about 2% of the adult populationi. The main symptom associated

... read more at: https://www.ptcommunity.com/wire/tetra-bio-pharma-provides-update-its-neuropathic-and-chronic-pain-drug-development-program